GLP-1 RAs efficacious for weight loss in overweight, obesity without diabetes
For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online Jan. 7 in the Annals of Internal Medicine.
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...
The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...
The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...
The FDA has approved the first generic form of liraglutide (Victoza), a once-daily injectable for improving glycemic control in patients ages 10 and older with type 2 diabetes, used as an adjunct to ...
HealthDay on MSN13d
FDA Approves Generic GLP-1 Medicine For Diabetes TreatmentThe U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback